Genenta Science S.p.A. (GNTA) Cash Flow Statement
Where GNTA’s cash came from and went, 2025
December 31, 2025 · euros- Cash from operations
- −€6.9M
- Capital expenditures
- €7,625
- Free cash flow
- −€6.9M
- Returned to shareholders
- —
- Change in cash
- €945,923 cash at year-end €5.5M
Drawn to scale: where the cash came from and how it was used. Hover for values.
GNTA operating cash flow, capex and free cash flow
GNTA cash flow trends, 2019–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −€2.5M2019 | −€6.9M2025 | — | |
| Capital expenditures | €20,8712019 | €7,6252025 | −15.4%/yr | |
| Free cash flow | −€2.5M2019 | −€6.9M2025 | — | |
| Stock-based compensation | €749,5122019 | €1.0M2025 | +5.1%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
GNTA cash flow by activity
GNTA net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
GNTA cash flow statement in euros
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Operating activities | |||||||
| Net income | −€6.5M | −€8.9M | −€11.6M | −€8.5M | −€5.5M | −€5.6M | −€4.6M |
| Depreciation & amortization | €28,082 | €44,523 | €42,453 | €6,140 | €4,889 | €1,900 | €1,900 |
| Stock-based compensation | €1.0M | €847,255 | €739,884 | €722,735 | €497,104 | €460,194 | €749,512 |
| Change in working capital | −€1.6M | €1.7M | −€417,597 | €240,297 | −€1.9M | −€920,717 | €1.4M |
| Other non-cash items | €203,018 | €63,112 | €75,692 | €90,355 | €13,231 | €6,056 | €2,967 |
| Cash from operating activities | −€6.9M | −€6.2M | −€11.2M | −€7.4M | −€7.0M | −€6.0M | −€2.5M |
| Investing activities | |||||||
| Capital expenditures | −€7,625 | −€4,468 | −€13,791 | −€27,070 | −€9,009 | −€20,871 | −€20,871 |
| Investments (net) | −€14.5M | €6.9M | −€14.9M | −€27,070 | −€9,009 | −€20,871 | €0 |
| Acquisitions & other investing | €0 | €4,468 | €13,791 | €27,070 | €9,009 | €20,871 | €0 |
| Cash from investing activities | −€14.5M | €6.9M | −€14.9M | −€27,070 | −€9,009 | −€20,871 | −€20,871 |
| Financing activities | |||||||
| Net borrowing (repayment) | €7.5M | €0 | €0 | — | — | — | — |
| Shares issued | €0 | €0 | €531 | €0 | €28.7M | €1.5M | €15.1M |
| Other financing | €14.8M | €270,885 | €0 | €0 | €543 | −€111,120 | −€318,506 |
| Cash from financing activities | €22.3M | €270,885 | €531 | €0 | €28.7M | €1.4M | €14.8M |
| Summary | |||||||
| Net change in cash | €945,923 | €890,329 | −€26.1M | −€7.4M | €21.8M | −€4.7M | €12.3M |
| Cash at end of period | €5.5M | €4.6M | €3.7M | €29.8M | €37.2M | €15.5M | €20.1M |
| Free cash flow | −€6.9M | −€6.2M | −€11.2M | −€7.4M | −€7.0M | −€6.1M | −€2.5M |
| Mar '26 | Sep '25 | Dec '24 | Jun '24 | Dec '23 | Sep '23 | Jun '23 | Mar '23 | Dec '22 | Sep '22 | Jun '22 | Mar '22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −€2.7M | −€4.2M | −€8.9M | −€4,038 | −€4,886 | −€2,443 | −€6.7M | −€6.4M | −€3.2M | −€2.1M | −€1.1M | −€1.5M |
| Depreciation & amortization | €14,035 | €13,861 | €22,102 | €22,258 | €21 | €11 | €20,946 | €3,326 | €1,663 | €2,812 | €1,407 | €2,802 |
| Stock-based compensation | — | €424 | €847,022 | €233 | €323 | €162 | €208 | €482,692 | — | €240,042 | — | — |
| Change in working capital | €512,134 | −€2.4M | €1.7M | €1,563 | €894 | €447 | −€1.3M | €293,122 | — | −€1.1M | — | −€628,186 |
| Other non-cash items | €466,533 | €584,774 | €6.3M | −€22,074 | €23 | €11 | €451,664 | €734,260 | €755,037 | €360,274 | −€228,343 | −€160,492 |
| Cash from operating activities | −€1.7M | −€6.0M | −€4,182 | −€2,058 | −€3,624 | −€1,812 | −€7.5M | −€4.9M | −€2.4M | −€2.6M | −€1.3M | −€2.3M |
| Investing activities | ||||||||||||
| Capital expenditures | −€477 | −€8,332 | −€4,466 | −€2,017 | −€1,484 | −€1 | −€12,321 | −€24,256 | −€12,128 | −€2,812 | −€1,407 | −€5,282 |
| Investments (net) | — | — | — | — | — | — | −€5.0M | −€5.0M | −€5.0M | −€5.0M | — | — |
| Acquisitions & other investing | −€10.3M | −€4.8M | €7,049 | €6,316 | −€3,407 | — | −€4.9M | €5.0M | €5.0M | €5.0M | €0 | €0 |
| Cash from investing activities | −€10.3M | −€4.8M | €2,583 | €4,299 | −€4,891 | — | −€9.9M | −€24,256 | −€12,128 | −€2,812 | −€1,407 | −€5,282 |
| Financing activities | ||||||||||||
| Shares issued | €0 | €0 | €0 | €0 | €0 | €0 | €0 | €0 | €0 | €0 | €0 | €0 |
| Other financing | €12.4M | €11.4M | €270,614 | €271 | €1 | €0 | — | — | — | — | — | €29.0M |
| Cash from financing activities | €12.4M | €11.4M | €270,614 | €271 | €1 | €0 | — | — | — | — | — | €29.0M |
| Summary | ||||||||||||
| Net change in cash | €353,534 | €1.3M | €4.6M | €6,187 | −€12,213 | −€4,261 | −€17.4M | −€2.4M | −€8.8M | −€1.3M | −€1.3M | €13.3M |
| Cash at end of period | €5.5M | €6.1M | €4.6M | €6,187 | €3.7M | −€4,261 | €12.2M | −€2.4M | €34,671 | €34.7M | €34,671 | €37.2M |
| Free cash flow | −€1.7M | −€6.0M | −€6.2M | −€2,060 | −€3,626 | −€1,813 | −€7.5M | −€4.9M | −€2.4M | −€2.6M | −€1.3M | −€2.3M |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in euros as reported; data from EODHD.
GNTA cash generation
In fiscal 2025 (ended December 31, 2025), Genenta Science S.p.A. generated -€6.9 million of cash from operations and spent €0.0 million on capital expenditures, leaving free cash flow of -€6.9 million. Cash and equivalents rose by €0.9 million over the year.
Related: GNTA income statement, GNTA balance sheet. See the GNTA stock overview for the latest quote and news.
GNTA cash flow FAQ
What is Genenta Science S.p.A.'s free cash flow?
Genenta Science S.p.A.'s free cash flow was -€6.9 million in fiscal 2025: -€6.9 million of operating cash flow minus €0.0 million of capital expenditures It was -€6.2 million a year earlier..
How much cash does Genenta Science S.p.A. generate from operations?
Genenta Science S.p.A. generated -€6.9 million of cash from operating activities in fiscal 2025.
How much does Genenta Science S.p.A. spend on capital expenditures?
Genenta Science S.p.A. spent €0.0 million on capital expenditures in fiscal 2025, compared with €0.0 million the year before.